

1
2
3 **Patients' lived experiences with antineoplastic medicines for the management of malignant solid**
4 **tumours: a systematic review**
5
6

7 **Abstract**
8

9 **Background:** Antineoplastic medicines affect the patients' physical and psychosocial well-being posing
10 challenges for patients, caregivers and healthcare professionals. However, little is known about the patients'
11 lived experience with medicines (PLEM) for antineoplastic treatment. It is the lived experience that gives
12 meaning to each individual's perception of a particular phenomenon which is influenced by internal and
13 external factors relevant to the individual.
14

15 **Objectives:** To critically appraise, synthesise and present the available evidence of patients' lived
16 experience with antineoplastic medicines prescribed for the management of malignant solid tumours.
17
18

19 **Method:** A systematic literature search was conducted in six electronic databases for articles published in
20 English with no date restrictions. The search terms were related to beliefs, practice and burden in relation
21 to patient, antineoplastic medicines, tumours and lived experience. Study selection, quality assessment and
22 data extraction were performed independently by 2 reviewers. Research findings were analysed using
23 narrative and meta-synthesis approaches.
24
25

26 **Results:** The search retrieved 31,004 articles with only 10 studies satisfying the inclusion and exclusion
27 criteria. These studies were published between 2005 and 2016 in Europe (n=6), America (n=3) and Asia
28 (n=1). Nine themes were identified to contribute to the patients' lived experience with antineoplastic
29 medicines. These were (a) influence from family members, healthcare professionals, media and culture, (b)
30 general attitude towards medicine, (c) accepting medicine, (d) modifying or altering medicine regimen or
31 dose, (e) medicine characteristics, (f) medicine routine, (g) medicine adverse events, (h) medicine and social
32 burden and (i) healthcare associated medicine burden. Patients tend to undergo a continuous process of
33 reinterpretations of their experience with medicines throughout their treatment journey.
34
35

36 **Conclusion:** The use of antineoplastic medicines has a profound effect on the patients' lives. Further
37 longitudinal in-depth studies are required to provide deeper insight into PLEM and support patients in their
38 treatment journey.
39

40 **Keywords:** solid tumor; antineoplastic medicines; patients' lived experience with medicine;
41 medicine-taking practice; medicine-related beliefs; medicine-related burden
42
43

44 **Abbreviations:**

45 PLEM - Patients' Lived Experience with Medicines

46 CASP - Critical Appraisal Skills Programme

47 EPHPP - Effective Public Health Practice Project

48 PRISMA-P - Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol

49 PROSPERO - International Prospective Register of Systematic Reviews
50
51
52
53
54
55
56

1
2
3 **Patients' lived experiences with antineoplastic medicines for the management of malignant solid**
4 **tumours: a systematic review**
5

6 Alison Brincat^a, Patricia Vella Bonanno^b, Derek Stewart^c, Anita E Weidmann^a

7
8 ^a School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen, Scotland

9 ^b Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow,
10 Scotland

11 ^c Qatar University Health and College of Pharmacy, Qatar University, Doha, Qatar
12
13

14
15 Corresponding author

16 Alison Brincat

17 e-mail: a.brincat@rgu.ac.uk

18
19 telephone: 00356 79933433

20
21 address: School of Pharmacy and Life Sciences, Robert Gordon University, The Sir Ian Wood Building,
22 Garthdee Road, Aberdeen, AB10 7GJ, Scotland
23
24

25
26 E-mail addresses of authors:

27 Patricia Vella Bonanno: patricia.vella-bonanno@strath.ac.uk

28
29 Derek Stewart: d.stewart@qu.edu.qa

30
31 Anita E Weidmann: a.e.weidmann@rgu.ac.uk
32
33

34 Declarations of interest: none
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

1
2
3
4 1 **Patients' lived experiences with antineoplastic medicines for the management of malignant solid**
5 2 **tumours: a systematic review**

6 3
7 4 **Abstract**
8 5

9 6 **Background:** Antineoplastic medicines affect the patients' physical and psychosocial well-being posing
10 7 challenges for patients, caregivers and healthcare professionals. However, little is known about the patients'
11 8 lived experience with medicines (PLEM) for antineoplastic treatment. It is the lived experience that gives
12 9 meaning to each individual's perception of a particular phenomenon which is influenced by internal and
13 10 external factors relevant to the individual.
14 11

15 12 **Objectives:** To critically appraise, synthesise and present the available evidence of patients' lived
16 13 experience with antineoplastic medicines prescribed for the management of malignant solid tumours.
17 14

18 15 **Method:** A systematic literature search was conducted in six electronic databases for articles published in
19 16 English with no date restrictions. The search terms were related to beliefs, practice and burden in relation
20 17 to patient, antineoplastic medicines, tumours and lived experience. Study selection, quality assessment and
21 18 data extraction were performed independently by 2 reviewers. Research findings were analysed using
22 19 narrative and meta-synthesis approaches.
23 20

24 21 **Results:** The search retrieved 31,004 articles with only 10 studies satisfying the inclusion and exclusion
25 22 criteria. These studies were published between 2005 and 2016 in Europe (n=6), America (n=3) and Asia
26 23 (n=1). Nine themes were identified to contribute to the patients' lived experience with antineoplastic
27 24 medicines. These were (a) influence from family members, healthcare professionals, media and culture, (b)
28 25 general attitude towards medicine, (c) accepting medicine, (d) modifying or altering medicine regimen or
29 26 dose, (e) medicine characteristics, (f) medicine routine, (g) medicine adverse events, (h) medicine and social
30 27 burden and (i) healthcare associated medicine burden. Patients tend to undergo a continuous process of
31 28 reinterpretations of their experience with medicines throughout their treatment journey.
32 29

33 30 **Conclusion:** The use of antineoplastic medicines has a profound effect on the patients' lives. Further
34 31 longitudinal in-depth studies are required to provide deeper insight into PLEM and support patients in their
35 32 treatment journey.
36 33

37 34 **Keywords:** solid tumor; antineoplastic medicines; patients' lived experience with medicine;
38 35 medicine-taking practice; medicine-related beliefs; medicine-related burden
39 36
40 37

41 38 **Abbreviations:**

42 39 PLEM - Patients' Lived Experience with Medicines

43 40 CASP - Critical Appraisal Skills Programme

44 41 EPHPP - Effective Public Health Practice Project

45 42 PRISMA-P - Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol

46 43 PROSPERO - International Prospective Register of Systematic Reviews
47
48
49
50
51
52
53
54
55
56

57
58
59 **45 Introduction**

46 Cancer is a group of related diseases featured by uncontrolled growth and dissemination of abnormal cells;
61 47 with more than 80% of all cancers being solid tumours.^{1,2} Cancers with the highest incidence amongst both
62 48 genders are solid tumours in the breast, lung, colorectum and prostate. More than 18 million patients were
63 49 newly diagnosed with cancer worldwide in 2018.³ It is being projected that by 2030 the number of newly
64 50 diagnosed cancer cases will rise to over 22 million per year predicted on the basis of an aging population
65 51 and adoption of behaviours linked with socio-economic development. Hence it is being considered as an
66 52 enormous international health burden growing at an alarming pace.^{2,4,5}
67 53

68 54 Antineoplastic medicines, which are often used as part of the treatment in combination with surgery and
69 55 radiation, interfere with cell growth resulting in apoptosis of cancer cells. Over the years, advances in cancer
70 56 care have led to prolonged cancer remission and management even when cure cannot be achieved. Hence
71 57 cancer is being considered as a chronic condition.^{2,6} The number of cancer survivors in America is expected
72 58 to increase from 15.5 million in 2015 to 20 million by 2026.⁷
73 59

74 60 Patients, themselves, are primarily responsible for the management of their health. Patient participation
75 61 within the healthcare systems includes the involvement of the patient in decision making, expressing
76 62 opinions about different treatment methods such as sharing of information, feelings and cooperating with
77 63 the healthcare professionals' advice. The concept of enabling active patient participation is increasingly
78 64 noted as a key component in the redesign of healthcare services and also as means to improve patient
79 65 safety.^{8,9}
80 66

81 67 The medicine experience incorporates the patient's description of his expectations, concerns, beliefs,
82 68 cultural, ethical and religious influences on medicine-taking behaviour. Cipolle *et al.* (2004) developed the
83 69 concept of medicine experience defined as "the sum of all the events a patient has in his/her lifetime that
84 70 involves drug therapy." This approach is emphasised in the practice of pharmaceutical care as it focuses
85 71 on patient-centred approach by providing direct care to patients based on their medicine-related needs.¹⁰
86 72 Similarly, Shoemaker and Ramalho de Oliveira in 2008 defined "the medication experience as an
87 73 individual's subjective experience of taking a medication in his daily life."¹¹ The concept of lived
88 74 experience stresses the fact that only those who have experienced the phenomena can communicate their
89 75 real experience to the outside world.^{12,13} A conceptual model of patients' lived experience with medicines
90 76 was compiled in a metasynthesis of qualitative studies by Mohammed *et al.* (2016). As depicted in
91 77 Figure 1, this incorporated medicine-related burden, medicine-related beliefs and medicine-taking practice.
92 78 These concepts will in turn affect the patients' wellbeing and health-related quality of life together with
93 79 therapeutic outcomes.¹⁴
80 80

94 81 Healthcare professionals' behaviours, family members and peers influence the patient's beliefs towards
95 82 medicines. The intensity of medicine-related burden and the coping skills of the individual influence the
96 83 patient's attitude and behaviour to the use of medicines. Positive attitudes arise from trust in healthcare
97 84 professionals, positive medicine experience and achievement of the desired therapeutic outcomes. The
98 85 medicine-related beliefs with the effect of the medicine-related burden influence the medicine-taking
99 86 practice.^{14,15} Medicine-related burden incorporates the medicine regimen, characteristics, adverse events
100 87 together with the social and healthcare effects. Mohammed *et al.* (2016) showed that intolerable medicine
101 88 burden often resulted in non-adherence and poor treatment outcomes.¹⁴ In addition, a study on 97 Australian
102 89 participants identified medicine-related burden as one of 4 interrelated components of treatment burden
103 90 (financial, time, travel and healthcare access burden) operating in a cyclical manner.¹⁶
104 91

105 92 The focus of cancer care is centred on improving patient experience by understanding the burden they meet
106 93 in everyday life, as well as the unmet needs of treatment such as treatment adverse effects and quality of
107 94 life. These insights can be achieved through direct and constructive interactions with patients.^{9,17}
108 95
109
110
111
112

113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168

96 The increasing number of publications including systematic reviews in the field of oncology indicates that
97 the care of cancer patients persists as a clinical research priority. The majority of the systematic reviews
98 evaluated cancer drug treatment effectiveness, safety and supportive care interventions.¹⁸ Despite this,
99 systematic reviews about medicine experiences of adult cancer patients undergoing antineoplastic treatment
100 are lacking. The aim of this systematic review was to critically appraise, synthesise and present the available
101 evidence of patients' lived experiences of antineoplastic medicines prescribed for the management of
102 malignant solid tumours.

103 **Method**
104 **Protocol registration**

105 A systematic review protocol was developed in accordance with the Preferred Reporting Items for
106 Systematic Reviews and Meta-Analyses Protocol (PRISMA-P) standards.¹⁹ The protocol was then
107 registered with International Prospective Register of Systematic Reviews (PROSPERO)
108 [PROSPERO2016:CRD42016048457] to avoid unplanned duplication of work.²⁰

109 **Eligibility criteria**

110 Studies were included in the systematic review if:

- 111 • the recruited patients were aged ≥ 18 years irrespective of their gender, ethnicity and stage of disease and
112 were receiving antineoplastic medicines for the management of malignant solid tumours in any setting;
113 and
- 114 • the views, experiences and behaviours of patients in receiving antineoplastic medicines from their
115 perspective were reported; and
- 116 • the study incorporated all the 3 aspects of the patients' lived experience with medicines concept:
117 medicine-related beliefs, medicine-related burden and medicine-taking practice as outcome measures.

118
119 Studies were excluded if they investigated the patient experience in experimental studies rather than the
120 'real world' setting, they included experiences of patients taking antineoplastic medicines solely for
121 palliative intent, studies reported in a non-English language or published as conference abstracts and grey
122 literature.

123 **Search strategy**

124 A database search strategy using specified search terms and their different combinations was created in
125 consultation with the research team. The key concepts of the patients' lived experience with medicines,
126 extracted from the model developed by Mohammed *et al.* (2016), were medicine-related burden, medicine
127 related-beliefs and medicine-taking practice. The search focused on these concepts in relation to patient,
128 antineoplastic medicines, malignant solid tumours and lived experience. Concept mapping was utilised as
129 an aid to consider all aspects of the topic and identify keywords that may be used for the search. The search
130 strategy was then adapted to meet the specifications of the different databases.

131 A systematic literature search was conducted in six databases: Cumulative Index to Nursing and Allied
132 Health Literature (CINAHL), Medline, Cochrane Database of Systematic Reviews, Embase, International
133 Pharmaceutical Abstracts and PsycArticles. The manual search of related studies in the references of
134 identified publications was carried out to identify additional potentially relevant papers.

135 **Study Review**

136 Screening was performed first on titles, then on abstracts and then followed by full papers in accordance to
137 the inclusion and exclusion criteria. A random sample of 10% of the retrieved titles and abstracts and the
138 whole list of full papers were screened independently by 2 members of the research team for consistency

169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224

139 of inclusion/exclusion and to enhance the reliability of the process. Any disagreement was resolved
140 following discussion and consensus was reached within the research team.

141 **Quality assessment**

142 Studies were appraised using quality appraisal forms adapted from the Critical appraisal skills programme
143 (CASP)²¹ and Equator Network²² for qualitative research together with the quality assessment tool of the
144 Effective public health practice project (EPHPP) for quantitative research.²³ Quality assessment was
145 performed independently by 2 reviewers. Any disagreements were discussed and resolved by consensus.

146 **Data extraction and synthesis of results**

147 Data extracted from the articles included specific details about the populations, study setting, research
148 design, method, salient findings and study limitations. The research findings of the quantitative and
149 qualitative studies were analysed using narrative and meta-synthesis approaches respectively. This
150 systematic review implemented the qualitative meta-interpretative synthesis (QIMS) methodology for
151 qualitative studies in an attempt to “create a new, deeper, and broader understanding” of the phenomenon.²⁴
152 QIMS allows the extracted data to be analysed through a process of coding, theme extraction, theme
153 synthesis and triangulation.^{25,26} After repeatedly reading the included studies, sections identified to fall
154 within one of the 3 main categories: (1) medicine-related beliefs, (2) medicine-taking practice and
155 (3) medicine-related burden in accordance to the model of Mohammed *et al.* (2016) were extracted and
156 reported verbatim in line with the corresponding theme. The quotes, if available, were pulled directly from
157 the study. This was independently done by the first researcher and another researcher within the team to
158 ensure that all extracts within the study were identified and grouped in the same category. Then the studies
159 were translated into each other. Proposed themes and sub-themes were put forward by all researchers
160 through an iterative process. The theme synthesis process utilises triangulation to enhance dependability
161 and trustworthiness of the findings. Triangulation is based on 4 processes, namely methods, sources,
162 analysts and theoretical perspectives.^{24,25}

163 **Bias**

164 The risk of bias was minimised by the application of the following measures:

- 165 • A random sample of 10% of studies identified during the database search was independently assessed
166 for relevance by two independent reviewers.
- 167 • Quality assessment using standardised critical appraisal instruments and data extraction of all selected
168 papers was conducted by two independent reviewers prior to inclusion in the review.
- 169 • Disagreements were resolved by consensus after discussion with the research team.

171 **Results**

172 **Study selection**

173 As shown in the Prisma flow diagram²⁷ (Figure 2), the combined search yielded 31,004 titles. A total of 10
174 studies met the inclusion criteria and were included in the systematic review.²⁸⁻³⁷ Two studies were
175 quantitative studies and 8 studies followed qualitative methodology.

176 **Description of the selected studies**

177 The characteristics of the included studies are summarised in Table 1. Studies were published between 2005
178 and 2016 and were conducted on 3 continents: Europe (n=6), America (n=3) and Asia (n=1). Sample sizes
179 ranged from 1 to 92 participants. Qualitative studies were conducted on 153 patients in total whilst
180 quantitative studies investigated 154 patients. Four studies included solely male participants whilst only 1
181 study involved only female participants in the sample population. Six studies investigated patients suffering

225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280

182 from a single cancer type: advanced non-small cell lung cancer (2 studies), breast cancer (3 studies) and
183 colorectal cancer (1 study). The remaining 4 studies did not focus on any particular cancer type but involved
184 patients suffering from various solid tumours. The treatment strategy varied across all 10 studies. Two
185 studies focused on patients receiving capecitabine, two studies included patients receiving erlotinib or
186 completed adjuvant antineoplastic treatment (fluorouracil, epirubicin and cyclophosphamide treatment
187 protocol) respectively and the other six studies involved patients receiving different antineoplastic treatment
188 protocols.

189 The majority of studies (n=8) used a range of qualitative methods which included focus groups (1 study),
190 open interviews (2 studies), semi-structured interviews (2 studies) or multi-method approach consisting of
191 observational study with semi-structured interviews with or without the use of field diary (3 studies). Two
192 further studies used a quantitative approach where data was collected using patient-reported questionnaires,
193 blood sampling and patient's medical files.

194
195 Out of the 10 studies, 3 studies did not state at which point in the patient's cancer journey the interview was
196 conducted. Six studies collected data during the patient's treatment phase whilst 1 study took a retrospective
197 look at patients who had completed chemotherapy within the previous year. Qualitative data of included
198 studies were analysed using content analysis, grounded theory and ethnography. Hence this systematic
199 review satisfied the 4 triangulation processes.

200 **Quality assessment of the included studies**

201 The quality assessment of the included studies is summarised in Appendices 1-4. The strengths of the
202 studies included a clear research aim in 80% (n=8) of the studies, an appropriate study design and the
203 attainment of ethical approval in all the studies except one where it was unclear whether ethical approval
204 was granted. The results obtained in the majority of the studies (n=8) clearly addressed the original research
205 question and the key findings were explained in detail.

206 The weaknesses of the selected studies included the lack of justification for the final sample size in the
207 manuscript (n=2) and the lack of discussion on the limitations of findings such as triangulation, bias and
208 confounders (n=8). The latter clarifies the extent to which the findings offer an accurate representation of
209 the phenomenon under study, hence affecting the validity and reliability of research findings.

210 **Data synthesis**

211 The studies included in this systematic review did not provide a standard definition of the patients' lived
212 experience with medicine. Nine themes emerged to highlight the patients' lived experience with
213 antineoplastic medicines in patients suffering from solid tumours: medicine-related beliefs (two themes),
214 medicine-taking practice (two themes) and medicine-related burden (five themes). The themes and
215 subthemes generated from this systematic review were mapped and presented in line with the structure of
216 the PLEM model (Figure 3) adapted from the conceptual model of Mohammed *et al.* (2016). Modifications
217 in the adapted model included the elimination of medicine related burden, magnitude and coping skills from
218 the main theme of medicine-related beliefs and the inclusion of the sub-themes within the model to ensure
219 a clear understanding.

220 **Medicine-related beliefs**

221 The identified themes within medicine-related beliefs included (a) influence of healthcare professionals,
222 family members, media and culture as well as (b) general attitude towards medicine.

223 *(a) Influence of family members, healthcare professionals, media and culture*

281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336

224 Chemotherapy, as a treatment, was found to be unique in being considered “*as the source of suffering*” both
225 culturally and medically.³¹ Suffering encompassed both a meaning and a value for each cancer patient. The
226 myths and stigma associated with cancer treatment may have silencing effects and may influence the
227 patient’s behaviour resulting in patients seeking support at a later stage of treatment.^{28, 31}

229 Patients tend to follow the healthcare professionals’ treatment recommendation to base their decision on
230 whether to initiate treatment or not. The trust of the patient in the healthcare professionals’ attitudes and
231 their relationship act as a driving force in their treatment decision and has a strong positive influence on
232 compliance with the medicine.^{28,33} “*I don’t know if I’m that brave yet, but if my doctors assured me this*
233 *was a good move, this was a good move for me, I feel confident enough in [my doctor] to follow his*
234 *advice.*”³³

236 Family members have also shown to be highly influential on patients’ beliefs and this was reflected in the
237 patients’ decisions regarding treatment. Patients disclosed their feelings of responsibility towards their
238 family members as they felt obliged to survive even if this was associated with suffering and restrictions.^{33,35}
239 “*Yes, I just thought that if something comes back again and I say no, then I have to look my family and*
240 *friends in the eye and say I could have prevented it, perhaps. Now, if something comes back again, I can*
241 *say I did everything I could. Cancer is bad enough without someone saying: It’s your own fault!!*”³⁵

243 Media and support groups have been found to strongly influence the cancer patient’s beliefs. Newly
244 diagnosed cancer patients may even obtain a false picture about cancer and its treatment from these sources
245 and this may provoke unnecessary anxiety.^{29,31} Cultural aspects also affect patients’ outlook on cancer and
246 its treatment as different cultures have diverse views on life, death and pain in general.^{28, 31}

248 (b) *General attitude of the patient towards medicine*

249 Chemotherapy is considered as one of the current treatment strategies that may lead to a disease-free future
250 and ultimately to survival.²⁸ Studies showed that prior to the initiation of treatment patients already had pre-
251 conceived notions and expectations about their treatment. A commonly expressed idea amongst patients is
252 that chemotherapy “*hurt the good cells and really hurting the cancer cells.*”^{30,31,35} Several feelings were
253 expressed by patients at initiation of treatment with antineoplastic medicines. These included hope^{28,33},
254 anxiety, stress^{29,35}, fear and also acceptance to carry the burden of side effects.³⁵ It was noted that although
255 chemotherapy provides grounds for “*hope*”³³, this is a highly feared form of treatment that is commonly
256 considered to be as bad or worse than the experience of cancer itself.^{30,31} Patients expressed concerns related
257 to aesthetic adverse effects such as hair loss, feeling of sickness and dependency on intake of medicines.³⁰
258 “*When I found out that I was going to have chemotherapy my whole world came apart. It was the worst*
259 *thing I could imagine.*”³⁰ As treatment cycles progressed, patients reported to feel calmer and more peaceful
260 (mean value of the mental component of SF-12 Health Survey improved from 47.1±7.5 at baseline to
261 50.4±5.4 at cycle 5).³⁷

263 When looking to the future, patients pondered if their current chemotherapy would be successful or whether
264 they would require to continue or change treatment. Patients were also concerned about the frequency of
265 follow-up visits with the oncologist, the monitoring of symptoms in relation to the disease and the adverse
266 effects in relation to treatment.^{28,29} Notwithstanding the fact that the negative feelings particularly in relation
267 to the side effects symptoms were still fresh in the patients’ minds, patients were worried about their ability
268 to continue with further chemotherapy sessions whilst coping with experience of their previous treatment.²⁹
269 “*...But I can’t think about if I were to find out that the cancer had spread, (and if I were to need more*
270 *treatment)—how would I then manage to go through chemotherapy again, now that I know about*
271 *everything, now that I have all the answers.*”²⁹ At the same time however they anticipated the time when
272 their treatment would be completed and were looking forward to a normal life. Some patients argued that
273 they perceived their life to have changed forever and were concerned about continuing to live their life

337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392

274 without treatment but with a lack of energy and a fear of disease recurrence. “*After treatment I want to*
275 *begin with a trip to the archipelago (islands that lie outside Stockholm) because that is where I get strength,*
276 *and I come out of there different, if you compare it to when you are in the city or town. I have been so close*
277 *to death and gone through this treatment—well, it is present all the time..I am going through counselling*
278 *right now, since I don’t want to put my family through the motions all the time..”²⁹*

280 **Medicine-taking practice**

281 The themes generated in relation to medicine-taking practice were (a) accepting medicine and (b) modifying
282 or altering medicine regimen or dose.

283 *(a) Accepting medicine*

284 Qualitative studies revealed that upon receiving the news of suffering from the life-threatening condition
285 of cancer, the focus shifted from diagnosis to treatment and survival.³⁵ Patients also wanted to know the
286 intent of treatment to be able to decide whether to undergo treatment and live longer; “*if this disease has*
287 *no cure you can tell me, because in this case I do not wish any treatment. ...He told me that that depends*
288 *on the case: if the disease is already too advanced, it is not worth to treat!”²⁸*

289
290 Patients claimed to be highly adherent to antineoplastic medicines.^{32,34,35} Quantitative studies in patients
291 receiving erlotinib showed that the mean adherence was 96.8% ± 4.0. ³⁴ Using the pill count method patients
292 treated with capecitabine showed a high adherence rate with only 8% (n=7) consuming less than 95% of
293 treatment whilst one patient was taking “*more than 105% of the prescribed dose.*” ³⁷

294 The treatment-free period between treatment cycles was medically prescribed interruption from treatment
295 either in accordance with the treatment protocol or due to adverse effects. Patients associated these breaks
296 as periods of relief and freedom from constraints to the medicine plan such as “*holidays*”³⁵ or as burdensome
297 periods with adverse effects with “*fear of recurrence.*”³³ This emphasised the importance of involving the
298 patient in treatment decision making and explanation of treatment.

299
300 Along the treatment journey, patients were building up their knowledge about the effects of chemotherapy,
301 interpreting the physical reactions experienced and developing coping mechanisms. Hence these patients
302 underwent a continuous process of reinterpreting their situation.²⁸ Collectively, patients described the
303 treatment journey in cancer as a “*degrading experience and anxiety-provoking*” as these patients had to
304 manage various side effects along the treatment phase. A fear of “*change*” was highly emphasised; this did
305 not only include the physical appearance especially in women but also the loss of the normal routine and
306 their identity as they may be considered as a cancer case.^{29,30} Although patients were learning to accept the
307 illness, they still wanted to maintain control over their body.³⁰

308 309 *(b) Modifying or altering medicine regimen or dose*

310 Patients, especially those receiving parenteral chemotherapy treatment, expressed their concern regarding
311 dose reduction and postponement of chemotherapy regimen by healthcare professionals.³¹ “*When the*
312 *oncologist offered to administer more chemotherapy cycles with a lowered dose, she enquired whether this*
313 *would still provide the optimal benefit and the oncologist replied “They’ve lowered lots of people”...She*
314 *was scared and had enquired with the oncologist whether this will cause the cancer to grow faster.”³¹ Self-*
315 *reported non-adherence measured by MARS showed increasing rates of modifications in treatment over*
316 *time ranging from 16% (n=12) at cycle 1 to 29% (n=16) at cycle 5.³⁷ Qualitative comments noted that*
317 *cancer patients receiving oral antineoplastic medicines may self-alter their prescribed treatment regimen*
318 *resulting in either under or over dosing of the treatment. The underdosing phenomenon may occur by*
319 *unintentionally missing or deliberately skipping a dose to reduce the severity of unbearable adverse effects*
320 *such as gastrointestinal symptoms. On the other hand, overdosing may occur when some patients claimed*

393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448

321 to consume the remaining forgotten medicines at the end of the cycle and a patient even admitted that “he
322 did not always respect the break in-between cycles.”^{32,34,37} Delays in chemotherapy schedule and dosage
323 reduction have instilled fears in making the tumour “*grow faster*” and promote recurrence. Most people
324 receiving cytotoxic chemotherapy seek to obtain certainty over uncertainty. The importance of taking
325 treatment exactly as prescribed and receiving “*100% dose*” was emphasised by the majority of patients.^{31,32}

327 **Medicine-related burden**

328 Five themes emerged for medicine related burden, these were (a) medicine characteristics (b) medicine
329 routine (c) medicine adverse events (d) medicine and social burden (e) healthcare associated medicine
330 burden.

331 (a) *Medication characteristics*

332 The patients’ experience in relation to medicine characteristics was adversely influenced by the dosage
333 form of treatment,³¹ colour of the parenteral infusion bag²⁹ and tablet size.³⁵ Patients recalled their physical
334 revulsion to the intake of oral antineoplastic formulation due to the size and form of the tablets that may be
335 too difficult to swallow, profound throat discomfort and the metallic after-taste.³⁵

336
337 Patients remarked that watching the nurse wearing the personal protective wear and following the procedure
338 to initiate the parenteral infusion created an appalling experience to the patient. This made them recall that
339 ultimately they would be experiencing adverse effects from such treatment. A patient metaphorised his
340 feeling as being “chained” to the infusion line. “*Especially the moment when the nurse entered the room*
341 *wearing protective gear and started the infusion, to be hooked up and to see the chemotherapy infuse the*
342 *blood vessel, and to know that this also will give some side effects was a terrifying experience.*”²⁹

344 (b) *Medicine routine*

345 In the qualitative studies, medicine routine burden considered aspects that related to the identification of
346 challenges in adapting to the incorporation of antineoplastic treatment into the patient’s lifestyle and
347 strategies to overcome these challenges. Patients made great effort to adhere to the prescribed doses and
348 schedules of chemotherapy due to the continuous awareness of the life-threatening nature of the illness
349 metaphorised as “*pills dominate the mind.*”^{32, 35} This attitude was the “only task that was not delegated to
350 others” as they felt that they “invested all their energy” so as to feel “actively engaged in fighting against”
351 cancer.³⁵

352
353 It appears that patients develop individualised treatment strategies to assist them with the adherence
354 procedure such as counting of tablets, preparing the tablets from the day before, storing the medicinal
355 product in a “*clearly visible prominent place*” or setting alarm on their mobile phone. More than 70% of
356 patients stated that they relied on the reminder method to support their treatment regimen. No association
357 was established between adherence as monitored with Medication Event Monitoring System and the
358 practice of the reminder method for erlotinib intake.³⁴ The use of the reminder method was noted in more
359 than 60% of patients receiving capecitabine at cycle 1 (61.5%, n=47), 3 (66.2%, n=44) and 5 (73.2%,
360 n=41).³⁷

361
362 Despite the patients’ determination to precisely adhere to the prescribed medicine plan, patients identified
363 barriers that could interfere with the adherence process. These include uncertainty in taking the correct
364 number of tablets, skipping the exact time for intake, disruption in their daily routine and running out of
365 pills.³⁵ Thirteen percent of patients (n=10) did not adjust the administration of capecitabine with meal
366 times at cycle 1, a behaviour that increased by 10.9% towards cycle 5.³⁷ This is comparable with 21% (n=8)
367 of patients in the study by Timmers *et al.* (2015) who did not follow the advice of taking erlotinib under
368 fasting conditions at 1 month. Using the generalised estimated equations, the occurrence of ocular

449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504

369 symptoms (p=0.031) and stomatitis (p=0.005) were found to be significantly increased with incorrect intake
370 of erlotinib without food.³⁴

371
372 (c) *Medicine adverse events*

373 Adverse events were considered as one of the most challenging aspects of living with antineoplastic
374 medicines. Patients referred to different adverse effects which ranged from minor to severe life-threatening
375 effects with the psychological and physical impact of these adverse effects affecting the patients' quality
376 of life.^{28,30,32,35,36} A cognitive decline manifested as lack of concentration, deteriorating memory and
377 dizziness was noted during and after antineoplastic treatment.^{30,35} Few participants reported of suffering
378 from mild cognitive impairment described as "empty head" and "fog" which adversely affected their
379 concentration.³⁶ A few patients considered it strange to suffer from symptoms caused by the treatment and
380 not from the actual illness.³⁰

381
382 The extent and severity of adverse effects due to antineoplastic treatment played a huge role in many
383 patients' attitudes.^{29,33} A female patient expected to feel better with every chemotherapy cycle however she
384 was frustrated when she started feeling side effects again.²⁸ All patient-reported symptoms were reported
385 to worsen from baseline to 1 month of treatment with erlotinib (with the exception of headache). Rash,
386 fatigue and cough were the three most common patient-reported symptoms after 2 months.³⁴ Thirty three
387 percent of patients blamed side effects for the discontinuation of treatment with capecitabine prior to
388 completion of the 5th cycle. The commonest patient-reported symptoms with capecitabine at cycle 5 were
389 hand and foot syndrome, fatigue and flatulence In view that these patients had already reported the
390 symptoms at baseline, were pre-treated and/or receiving capecitabine concomitantly with
391 oxalplatin/irinotecan, it is difficult to attribute these adverse effects solely to capecitabine.³⁷

392 The majority of patients were still experiencing side effects after stopping treatment, with effects being
393 cumulative and worsening over time. However, several patients were surprised to experience relatively few
394 side effects during their course of chemotherapy, both for orally and parenterally administered
395 antineoplastic treatment.³¹

396
397 The aspect of "*suffering*" is so ingrained with the experience of chemotherapy that it is not even recognised
398 as an adverse effect of treatment.³¹ Hence patients failed to recognise adverse effects from these medicines
399 and refrained to inform the healthcare professionals about the occurrence and severity of adverse effects
400 they experienced.^{28,32,35} The patient's ability to tolerate the adverse effects is associated with the concept of
401 making an effort to achieve cure or disease control and may be considered as the "*price to pay*" for treatment
402 efficacy.³² Patients face adverse effects differently, they either accept to support their adverse effects and
403 have a fatalist attitude or they resort to complementary medicine such as phototherapy, homeopathy and
404 hypnotism. The focus groups discussions revealed that patients wait between 3 and 8 days prior to
405 consulting medical advice. Some cancer patients even tried to hide or minimise their adverse effects by
406 either not considering them as severe or by preferring not to talk about them.^{32,35} The latter may be the result
407 of feeling afraid that the oncologist would change their treatment and hence reduce the possibility of a
408 positive response. Few patients felt uncomfortable to speak about adverse effects during every appointment
409 or to discuss specific intimate adverse effects such as vaginal dryness.^{30, 32, 35}

410
411 (d) *Medicine and social burden*

412 Despite having treatment, patients put all their efforts to be as positive as possible and lead a normal life.
413 They realised the significance of every day and felt determined to appreciate their lives.^{30,36} "*But because*
414 *of the experience of illness, I realize how precious each day and normal life is.*"³⁰

505
506
507 416 Antineoplastic medicines affect the patient's social life which is directly related to their quality of life.
508 417 Patients experienced social isolation often due to altered relationships with family members and
509 418 friends.^{29,30,35,36} This may be the result of adverse effects, complex treatment regimen or social stigma. As
510 419 treatment became the focal point of the cancer patients' lives, this also dominated both their social and
511 420 family life. *"I stopped playing with the orchestra in November of last year. That also has something to do
512 421 with (name of medication); I got shaky and it had a few other side effects than with (intravenous) chemo."*³⁵
513 422 Patients described this period as hard to get through and they focused all their efforts on their feelings. *"And
514 423 then there was the constant worry that the lab tests wouldn't be good so that everything would have to be
515 424 postponed, and my whole life was about this.."*³⁰
516 425

517 426 In contrast, cancer patients recognised the support provided by family members for proper medicines use
518 427 and the benefits of support groups.^{29, 30, 33, 35, 36} The illness was described as a dramatic, traumatic and insane
519 428 experience for the family. Family members offer paramount support to cancer patients, with the role of the
520 429 spouse often considered as a *"lifeline"*.³⁰ The partners were specifically identified as providing aid in the
521 430 patients' daily life such as doing the household chores as this allows the patients to rest when they felt
522 431 tired.³⁵ However there were other patients who felt as if their family did not take any extra consideration.
523 432 The necessities of time and support to the patient from their relatives was usually overlooked, demonstrating
524 433 the importance that relatives are aware of the patient's requirements.³⁰
525 434

526 435 Patients also spoke about the impact of treatment on the patients' work and financial income bringing about
527 436 instability in life. *"Chemotherapy brings a lot of anxiety, because I don't know if I can accept an order for
528 437 or not. You know, there is no lack of work, but if you don't deliver as promised the costumers forget about
529 438 you. It's bad time for work now.... But it'll become better."*²⁸ Patients, predominantly females, voiced a
530 439 sense of gratitude for being granted sick leave during their treatment period. This provided time to
531 440 completely devote their life to themselves. Patients disclosed their difficulties in returning back to their
532 441 workplace. They described feeling pressured from society and healthcare professionals to return to their
533 442 workplace as early as possible. The patients' inner worry was that their employer expected to receive the
534 443 same work output like before their diagnosis. Some women explained that specific work environments,
535 444 such as working with children, may result in a higher risk of contracting infections. This may have
536 445 contributed to their decision not to return to work during treatment. Some women narrated that when they
537 446 spoke about cancer at the work place; this proved to be taken negatively both by employers and work
538 447 colleagues.³⁰ *"But then I noticed, and when I came back and started to work full-time my boss came to me
539 448 and said that this position I had applied for had gone to someone else because I had to think of my illness."*³⁰
540 449 Those cancer patients who persisted with the working life had noted that work became important part of
541 450 life and aided them to detach themselves from the illness itself.^{28,30}
542 451

543 452 (e) Healthcare associated medicine burden

545 453 Challenges associated with the complexity of the healthcare system were identified. Healthcare
546 454 professional-patient relationships,^{29,30} patient-patient relationships,²⁹ healthcare support^{29,30} and provision
547 455 of information³⁰ were commonly described. Cancer patients looked for professionalism and traits such as
548 456 empathy, respect and good support from healthcare professionals. The support offered by healthcare
549 457 professionals was overall rated as positive.^{29,30} *"Well the important thing is of course how they care for
550 458 you, and not that it has to be so incredibly professional so that, that...Empathy is alpha and omega. And I
551 459 think they are good and I always tell them that when they ask."*³⁰ Provision of good quality information
552 460 from healthcare professionals delivered at the appropriate time was considered to be important and made a
553 461 positive effect in the patients' experiences. In fact, patients felt the large amount of information delivered,
554 462 especially during the meeting when the oncologist broke the news about their diagnosis, as very
555 463 *"stressful"*.^{29,30,32} Patients described that healthcare professionals should consider each patient to know

561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616

464 nothing about the disease and the treatment and fulfil their information needs with plain, correct and clear
465 material.³⁰

466 Cancer patients identified transportation, distance to hospital for multiple visits, hospital waiting time,
467 companionship with caregivers to treatment and financial burden as barriers to treatment. These difficulties
468 decreased the patients' enthusiasm to continue long-term maintenance treatment with antineoplastic
469 maintenance.^{29,33} *"I live alone as well, and every time I come for chemo or transfusions I have to have*
470 *someone bring me. So that would—if I had to come real frequently that would put a hardship on."*³³ Patients
471 commented on the lack of tranquil hospital environment and individualised support by hospital staff.
472 Although the patients receiving oral antineoplastic treatment in the comfort of their own home was
473 considered to be a major advantage, they complained of insecurity about not receiving professional
474 counselling and support at home.^{29, 35}

475
476 Some patients felt that other patients may offer companionship and moral support particularly when they
477 accompany one another during treatment cycles. During the chemotherapy outpatient clinic, cancer patients
478 interacted with each other and also served as a network of support. They would transmit to each other
479 positivism, strength and a feeling of unity.^{28, 30} *"Yes, it is very important to have someone to share this with*
480 *because other people do not know what you're talking about. You can explain but they do not know what*
481 *chemotherapy treatment is."*³⁰ Whilst being an in-patient to receive parenteral treatment, one patient even
482 praised the consideration of healthcare professionals who ensured patients of similar age and treatment
483 share the same hospital room. However others mentioned the negative psychological impact in the
484 announcement that a patient in their group is suffering from a terminal disease which will reasonably result
485 into death within a short period of time. *"For the first treatment I was placed in a four-bed room and I*
486 *remembered that I thought it was so hard, really hard; for one thing, I had just found out my diagnosis....and*
487 *then you just see old people and it gets so obvious what am I doing here. You know it was absolute, I didn't*
488 *want to be there with all the drainage bags they had, and it was hard. But since then it has been so nice*
489 *because I was able to change rooms and she (another patient) is the same age as me; we do the treatment*
490 *together and I think it's great that they have scheduled us together and that we can share a room."*²⁹

491
492 Patients enquired about the lack of available treatments despite the ongoing research in oncology.^{31,33} A
493 cancer patient made reference to fluorouracil, a standard antineoplastic medicine which has been available
494 for the past 20 years and is still in use; hence can be considered as quite an old drug. He considered this as
495 a bad thing in the light that continuous research is being conducted in this field and remarked, *"Surely we*
496 *can do better than that!"*³¹

497 **Discussion**

498 The systematic review indicates that none of the published papers provided a standard definition of the
499 patients' lived experience with medicine. The systematic review showed that PLEM is a highly subjective
500 and complex concept, with a lot of considerations. Hence this systematic review supports the model which
501 offers a better framework for PLEM. The model developed by Mohammed *et al.* (2016) is comprehensive
502 and encapsulates the important aspects in PLEM. This systematic review identified lack of studies with
503 none of the identified studies making use of the PLEM model. Despite the inclusion of a small number of
504 studies in this systematic review, this has captured all the themes related to medicine-related beliefs,
505 medicine-taking practice and medicine-related burden mentioned in the model by Mohammed *et al.* (2016).
506 Hence, this model is likely to be transferable to the oncology setting with slight modifications.¹⁷

507
508 Collectively researchers provided an extensive account on beliefs, practice and burden of patients receiving
509 different antineoplastic medicines. Patients considered this treatment either as hope or worse than the illness
510 itself. This systematic review showed that patients' treatment decision was highly influenced by the
511 healthcare providers' and carers' preferences. Patients should be informed about all treatment options and
512 be part of the treatment decision in order to be recognised as equal partners in the healthcare team.^{38,39}

617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672

513 The introduction of oral antineoplastic agents has altered the outlook of provision of cancer treatment from
514 a controlled monitored procedure in hospital for parenteral treatment to individualised responsibility in the
515 patient's home. This created a major shift in the roles of healthcare professionals mostly doctors, nurses
516 and pharmacists onto patients and carers.⁴⁰ Experienced patients who had received different antineoplastic
517 treatments argued that intravenous chemotherapy necessitates an autonomous behaviour solely for
518 managing side effects. On the other hand, the medicine-taking practice together with the monitoring of
519 adverse effects of oral antineoplastic is more dependent on the patient's autonomy. This systematic review
520 showed that patients voiced their concern that information about treatment was given by healthcare
521 professionals at a time when they were not able to fully comprehend and pose the necessary questions.
522 Hence patients expressed their need of treatment-specific education in a consistent and practical manner for
523 the complex antineoplastic treatment regimens.⁴¹

525 Research showed that patient adherence to long term treatment was no more than 50% but seems to be
526 higher in case of antineoplastic treatment. Although there are multiple reasons for this, it is highly associated
527 with the perceived fatal implications of cancer.⁴² This was consistent with our systematic review where
528 patients were noted to be highly adherent to treatment. Patients noted that forgetting to take the treatment
529 was often due to an alteration in their daily routine such as going on vacation or visiting friends. They also
530 described of being in doubt whether they had taken the right amount of tablets or whether they had failed
531 to take the treatment at the exact time.^{32,35} Patients who had received various antineoplastic treatments had
532 a risk of developing more secondary effects which may result in lack of adherence and poor concordance
533 to the current prescribed treatment. Therefore, the patients necessitate specific advice when changing from
534 one medicine to another.³²

536 This systematic review identified misconceptions that patients had about treatment especially in relation to
537 efficacy. From a biomedical perspective, chemotherapy in oral formulation has similar efficacy as
538 parenteral and hence is certainly not associated to treat less 'serious' cancers. Other patients believed that
539 they were suffering from a milder cancer compared to other patients as they were receiving oral
540 chemotherapy.³¹ Patients did not always understand or were provided with the rationale behind certain
541 requirements of the treatment. For instance, breaks between treatments were either medically prescribed
542 interruptions according to treatment protocol or due to the occurrence of adverse effects. Patients associated
543 these breaks as periods of relief and freedom from constraints to the medicine plan such as 'holidays' or as
544 burdensome periods with worsening of adverse effects and fear of recurrence.^{33,35} This emphasised the
545 importance of involving patients in decision making about their treatment and the explanation of
546 treatment.³²

548 During the treatment journey patients are not only experiencing physical effects but also psychological
549 effects with a myriad of emotions. As a result of fear of modification or discontinuation of treatment,
550 patients delay in reporting adverse effects to healthcare professionals.^{32,35} However, patients who
551 experienced minimal adverse effects thought that their treatment was not effective. This induced
552 unnecessary concern and stress to the patients.^{28,30}

554 Consistent with other studies, nausea and vomiting are the most common adverse drug reactions
555 experienced by patients. Studies showed that patients required increased doses of anti-emetic treatment in
556 order to manage these symptoms. Due to the common occurrence of adverse effects with antineoplastic
557 medicine, it is vital that patients would be able to identify these toxicities and be advised on what measures
558 to follow.^{29,36,41} Reasons provided by patients about lack of reporting of adverse effects were uncertainty
559 about severity of adverse effects, fear of withholding treatment and waiting for the next appointment rather
560 than contacting the healthcare professional immediately. Delayed reporting of adverse effects to healthcare
561 professionals may lead to a detrimental effect to the patients themselves.³²

673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728

562 Cancer treatment transformed and dominated the patient's social and family life. The patients
563 acknowledged support from family members, peers, support groups and healthcare professionals during
564 their treatment and also their need to develop coping skills.^{29,30,33,35,36} This will identify the importance of
565 the provision of holistic care to the patients with cancer at all stages of the treatment journey, taking into
566 consideration their physical, psychological, social and spiritual well-being. This systematic review will
567 empower healthcare professionals to consider all the aspects of PLEM in their practice in the area of cancer
568 treatment in order to help patients achieve a better quality of life during the treatment journey. The
569 complexity of cancer treatment necessitates more patient involvement. Interprofessional collaboration
570 between healthcare professionals in primary and tertiary settings together with the carer are needed to
571 ensure services that meet the patient's needs. Educational and motivational strategies adapted and re-
572 enforced at different time-points during the treatment are necessary to address issues particularly related to
573 aspects of burden.

574
575 Future research should focus on interventions that may be practiced by healthcare professionals to enhance
576 patient's empowerment and encourage patients to take more active role in their cancer treatment. Studies
577 should also be conducted on patients refusing to initiate or discontinue treatment with antineoplastic
578 medicines to understand their beliefs, perceptions and attitudes.

579 **Limitations**

580 This systematic review followed a comprehensive search strategy in six databases since their respective
581 inception. Identification of studies and data extraction was performed by 2 independent reviewers so as to
582 reduce bias and improve the rigour. However this systematic review has its limitations. The included studies
583 had to focus on the whole concept of PLEM, which means that all 3 themes of medicine-related burden,
584 medicine-taking practice and medicine-related beliefs had to be discussed in the same publication. This is
585 due to the overwhelming amount of publications focusing on one particular aspect and to offer researchers
586 a broad complete picture of the inter-relationship between the 3 themes in a particular setting experienced
587 by the patient. Studies that assess adherence to antineoplastic agents have been conducted but this
588 systematic review included only those studies that also involved medicine-related beliefs and medicine-
589 related burden. Therefore adherence to antineoplastic medicines is being discussed in relation to a holistic
590 aspect of the patients' lived experience with medicines. This systematic review relied on secondary data
591 and combined data from different methodologies and of different quality. Hence this resulted in the
592 provision of limited detail to the authors and increased the element of bias in the interpretation of the results.
593 The review only included studies published in English, which might have resulted in publication bias. In
594 addition, grey literature including conference abstracts was not included in this review. Since the review
595 included studies conducted in different countries and settings, patients provided their experiences based on
596 their healthcare systems which may vary from country to country. Although all patients were suffering from
597 solid tumours and receiving antineoplastic medicines, different cancer types may require diverse treatment
598 regimens which vary in complexity. This may lead to increased heterogeneity of the review results. Various
599 confounding factors such as patient characteristics, comorbidities, environmental factors and time-points in
600 the treatment journey when the study was conducted may have affected the findings.

601 **Conclusion**

602 This systematic review elicits a comprehensive assessment of the patients' needs which is crucial for
603 patient-centred care. The adapted model of PLEM for patients with solid tumours receiving antineoplastic
604 medicines explains the dynamic processes and socio-cultural influences that affect medicine-related beliefs,
605 medicine-taking practice and medicine-related burden. It shows that patients undergo a continuous process
606 of reinterpretations of the phenomenon along the treatment journey.

607
608 Patients are experts by experience as they provide a unique perspective on their disease state and required
609 care. The understanding of the patients' experience with the antineoplastic medicines sheds light on the

610 patients' needs and support services needed during this journey. This will ultimately lead to better health
611 outcomes and improved quality of healthcare services.

612
613 **Conflict of interest:** None

614 **Funding:** This research did not receive any specific grant from funding agencies in the public,
615 commercial, or not-for-profit sectors.

616 **References**

- 617 1. Chaddah, M. Stem Cell Network. Cancers: solid tumor.
618 [https://pdfs.semanticscholar.org/fe02/ee8c0df114696097eae43b2439fe2209b80c.pdf?_ga=2.40667362.1](https://pdfs.semanticscholar.org/fe02/ee8c0df114696097eae43b2439fe2209b80c.pdf?_ga=2.40667362.122135331.1548737665-1120820608.1548737665)
619 [122135331.1548737665-1120820608.1548737665](https://pdfs.semanticscholar.org/fe02/ee8c0df114696097eae43b2439fe2209b80c.pdf?_ga=2.40667362.122135331.1548737665-1120820608.1548737665); 2013 Accessed 13.12.18.
- 620 2. American Cancer Society. (2018) Cancer Facts and Figures. [https://www.cancer.org/content/dam/cancer-](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf)
621 [org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf)
622 [2018.pdf](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf); 2018 Accessed 13.12.18.
- 623 3. International agency for research on cancer and World Health Organisation. Cancer today.
624 http://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf; 2018 Accessed
625 13.12.18.
- 626 4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. *Ca Cancer J Clin.*
627 2011;61:69-90.
- 628 5. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human
629 Development Index (2008–2030): a population-based study. *The Lancet Oncology.* 2012;13:790–801.
- 630 6. Phillips JL, Currow DC. Cancer as a chronic disease. *Collegian.* 2010;17:47-50.
- 631 7. Miller KD, Siegel RL, Lin CC. et al. Cancer Treatment and Survivorship Statistics. *Ca Cancer J Clin.*
632 2016;66:271-289.
- 633 8. Longtin Y, Sax H, Leape LL, Sheridan SE, Donaldson L, Pittet D. Patient participation: current
634 knowledge and applicability to patient safety. *Mayo Clinic proceedings.* 2010;85:53-62.
- 635 9. Hoos A, Anderson J, Boutin M, Dewulf L, Geissler J, Johnston G, Joos, A., Metcalf M, Regnante J,
636 Sargeant I, Schneider RF, Todaro V, Tougas, G. (2015). Partnering With Patients in the Development and
637 Lifecycle of Medicines: A Call for Action. *Therapeutic innovation & regulatory science.* 2015;49:929-
638 939.
- 639 10. Cipolle RJ, Strand LM, Morley PC. *Pharmaceutical care practice: The clinician's guide.* 2nd ed. New
640 York: McGraw Hill; 2004.
- 641 11. Shoemaker SJ, Ramalho de Oliveira D. Understanding the meaning of medications for patients: the
642 medication experience. *Pharm World Sci.* 2008;30:86-91.
- 643 12. Todres L, Holloway I. Descriptive phenomenology: Life-world as evidence. In: Rapport F, ed. *New*
644 *qualitative methodologies in health and social care research.* London: Routledge; 2004.
- 645 13. Mapp T. Understanding phenomenology: the lived experience. *British Journal of Midwifery*
646 2008;16:308–311.
- 647 14. Mohammed MA, Moles RJ, Chen TF. Medication-related burden and patients' lived experience with
648 medicine: a systematic review and metasynthesis of qualitative studies. *BMJ Open.* 2016;6:e010035.
- 649 15. Tordoff J, Simonsen K, Thomson WM, Norris PT. "It's just routine." A qualitative study of medicine-
650 taking amongst older people in New Zealand. *Pharm World Sci.* 2010;32:154-161.
- 651 16. Sav A, Kendall E, McMillan SS, Kelly F, Whitty JA., King MA, Wheeler AJ. 'You say treatment, I say
652 hard work': treatment burden among people with chronic illness and their carers in Australia. *Health and*
653 *Social Care in the Community.* 2013;21:665-674.
- 654 17. Koczwara B. *Cancer and chronic conditions.* Singapore: Springer Science and Business Media; 2016.
- 655 18. Goldkuhle M, Narayan VM, Weigl A, Dahm, P, Skoetz N. A systematic assessment of Cochrane
656 reviews and systematic reviews published in high-impact medical journals related to cancer. *BMJ*
657 *Open.* 2018;8:e020869.

785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840

- 658 19. PRISMA. PRISMA for systematic review protocols (PRISMA-P) <http://www.prisma-statement.org/Extensions/Protocols.aspx>; 2015 Accessed 03.12.18.
- 659 20. Brincat A, Vella Bonanno P, Stewart D, Weidmann A. Patients' lived experiences of cytotoxic
660 medications prescribed for the management of malignant solid tumours: a systematic review.
661 http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42016048457; 2016
662 Accessed 23.11.18
- 663 21. Critical appraisal skills programme. CASP Checklist. <http://www.casp-uk.net/casp-tools-checklists>; 2017
664 Accessed 03.12.18.
- 665 22. Equator Centre. Equator Network: Enhancing the quality and transparency of health research.
666 <https://www.equator-network.org/>; 2018 Accessed 24.11.18.
- 667 23. McMaster University. Effective Public Health Practice Project. Quality Assessment Tool for quantitative
668 studies (2012-2018). <https://merst.ca/ephpp/>; 2018 Accessed 23.11.18
- 669 24. Aguirre RT, Bolton KW. Qualitative interpretive meta-synthesis in social work research: Uncharted
670 territory. *Journal of Social Work*. 2013;14:279-294.
- 671 25. Maxwell D, Robinson SR, Rogers K. "I keep it to myself": A qualitative meta-interpretive synthesis of
672 experiences of postpartum depression among marginalised women. *Health & Social Care in the*
673 *Community*. 2018 [Epub ahead of print]
- 674 26. Nye E, Melendez-Torres GJ, Bonell C. Origins, methods and advances in qualitative meta-synthesis. *Rev*
675 *Educ*. 2016;4:57-79.
- 676 27. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for
677 Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med*. 2009;6:e1000097
- 678 28. Yokoyama dos Anjos AC, Zago MMF. The Cancer Chemotherapy experience in a patient's view. *Revista*
679 *Latin-Americana de Enfermagem* 2005;14:1-8
- 680 29. Bergkvist K, Wengstrom Y. Symptom experiences during chemotherapy treatment-with focus on nausea
681 and vomiting. *European Journal of Oncology Nursing*. 2006;10:21-29.
- 682 30. Browall M, Gaston-Johansson F, Danielson E. Postmenopausal women with breast cancer. *Cancer*
683 *Nursing*. 2006;29:34-42.
- 684 31. Bell K. 'If it almost kills you that means it's working!' Cultural models of chemotherapy expressed in a
685 cancer support group. *Social Science & Medicine*. 2009;68:169-176.
- 686 32. Regnier Denois V, Poirson J, Nourissat A, Jacquin, JP, Guastalla, JP, Chauvin F. Adherence with oral
687 chemotherapy: results from a qualitative study of the behaviour and representations of patients and
688 oncologists. *European Journal of Cancer Care*. 2011;20:520-527.
- 689 33. Gerber DE, Hamann HA, Rasco DW, Woodruff S, Craddock Lee J. Patient Comprehension and attitudes
690 toward maintenance chemotherapy for lung cancer. *Patient Education and Counseling*. 2012;89:102-108.
- 691 34. Timmers L, Boons CCLM., Moes-ten Hove J, Smit EF, van de Ven PM, Aerts JG, Swart EL, Boven E,
692 Hugtenburg JG. Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell
693 lung cancer. *Journal of Cancer Research and Clinical Oncology*. 2015;141:1481-1491.
- 694 35. Gassmann C, Kolbe N, Brenner A. Experiences and coping strategies of oncology patients undergoing
695 oral chemotherapy: first steps of a grounded theory study. *European Journal of Oncology Nursing*.
696 2016;23:106-114.
- 697 36. Komatsu H, Yagasaki K, Yamauchi H, Yamauchi, T. Patients' perspectives on creating a personal safety
698 net during chemotherapy. *Clinical Journal of Oncology Nursing*. 2016;20:13-16.
- 699 37. Timmers L, Boons CCLM, Mangnus D, van de Ven PM, Van den Berg PH, Aart B, Swart EL, Honeywell
700 RJ, Peters GJ, Boven E, Hugtenburg, JG. Adherence and patients' experiences with the use of capecitabine
701 in daily practice. *Frontiers in Pharmacology*. 2016;7:1-10.
- 702 38. Pomey MP, Ghadiri DP, Karazivan P, Fernandez N, Clavel N. Patients as Partners: A Qualitative Study
703 of Patients' Engagement in Their Health Care. *PLoS ONE*. 2015;10:e0122499.
- 704 39. Vahdat S, Hamzehgardeshi L, Hessam S, Hamzehgardeshi, Z. Patient Involvement in Health Care
705 Decision Making: A Review. *Iranian Red Crescent Medical Journal*. 2014;16:e12454.
- 706 40. Tadic D, Bozovic Spasojevic I, Tomasevic ZI, Dejanovic SD. Oral administration of antineoplastic
707 agents: the challenges for healthcare professionals. *JBUON* 2015; 20:690-698.

841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896

709 41.Chopra D, Rehan HS, Sharma V, Ritu Mishra R. Chemotherapy-induced adverse drug reactions in
710 oncology patients: A prospective observational survey. *Indian J Med Paediatr Oncol.* 2016;37:42–46.
711 42.Barillet M, Prevost V, Joly F, Clarisse B. Oral antineoplastic agents: how do we care about adherence? *Br*
712 *J Clin Pharmacol.* 2015;80:1289-1302.
713




Figure 1 Conceptual model of the patients' lived experience with medicine (PLEM) as developed by Mohammed *et al.* (2016). The model shows the complexity of PLEM and an inter-relationship between medicine related burden, medicine related beliefs, medicine taking practice.

Adopted from: Mohammed MA, Moles RJ, Chen TF. Medication-related burden and patients' lived experience with medicine: a systematic review and metasynthesis of qualitative studies. *BMJ Open.* 2016;6:e010035.




Figure 2 Prisma flow diagram showing the inclusion and exclusion of studies identified for the systematic review. Reasons for the studies being excluded are also provided. Adapted from Prisma 2009 flow diagram.²⁷




Figure 3 An adapted model of PLEM for patients with solid tumours receiving antineoplastic medicines

Table 1 Information about the studies included in the systematic review arranged in chronological order

Study [Authors, year, country]	Stated aim(s) and objective(s)	Setting and number of respondents	Study design	Method of data collection	Data analysis	Key findings
Yokoyama dos Anjos and Zago, 2005, Brazil	To understand the meaning of the chemotherapy from the patient's point of view	Oncology hospital and patient's home, n=1	Qualitative ethnographic case study	<ul style="list-style-type: none"> • Semi-structured interviews • non-structured observations • patient's field diary 	Interpretative anthropology	<p>Seven unities of meaning were identified:</p> <ol style="list-style-type: none"> 1. discovery of cancer and search for assistance, 2. knowledge about cancer, 3. trajectory of chemotherapy, 4. networks of support, 5. lack of control of one's life, 6. uncertainty about the future, 7. expectation in the future. <p>The patient's view on her experience with cancer chemotherapy as "the loss of the control over one's life" were summarised. The study emphasised the need for nurse care to follow up the patient throughout the whole process and offer resources to the patient to resume control of her life during this critical period.</p>
Bergkvist and Wengstrom, 2006, Sweden	To acquire a deeper understanding of cancer patients' symptom experiences with focus on nausea and vomiting during chemotherapy treatment and the consequences these have on daily life	Oncology hospital, n=9	Qualitative study	Semi-structured interviews	Content analysis	<p>Five main categories in the experience of chemotherapy treatment were identified:</p> <ol style="list-style-type: none"> 1. before cancer diagnosis, 2. being ill—consequences on daily life, 3. going through chemotherapy treatment, 4. coping with treatment, 5. after treatment—looking forward to a normal life. <p>The study describes that the experience of receiving chemotherapy is a process that evolves over time. The findings suggest that experiences of nausea and vomiting during chemotherapy treatment have a profound effect on the cancer experience and thus may influence future decisions relating to new treatment.</p>

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84

<p>Browall, Gaston-Johansson and Danielson, 2006, Sweden</p>	<p>To describe the experience of postmenopausal women with breast cancer who undergo adjuvant chemotherapy treatment</p>	<p>Oncology hospital and patient's home, n=20</p>	<p>Qualitative study</p>	<p>Narrative interviews with one open question</p>	<p>Content analysis</p>	<p>Four themes were identified: 1. the fear of the unknown, 2. affects on body and mind, 3. to get by, 4. a transformed life.</p> <p>The participants described feelings of imbalance in their relationships due to lack of support from those close to them. The support from healthcare professionals was experienced both positively and negatively; with most of the participants revealing variations in the healthcare professionals' attitude, knowledge, and empathy. Women who decided not to work during the treatment felt pressure from society and healthcare professionals to get back to work as soon as possible. The participants expressed a feeling of not being afraid of dying but wanted more time to prepare themselves.</p>
<p>Bell, 2009, Canada</p>	<p>To explore patients' perceptions of adjuvant chemotherapy</p>	<p>Cancer support group, n=8</p>	<p>Ethnography</p>	<ul style="list-style-type: none"> • Semi-structured interviews • participant observation at the support group meetings 	<p>Thematic analysis</p>	<p>Three themes were identified: 1. Hurting the good cells & really hurting cancer cells, 2. Getting a "full dose", 3. Oral vs intravenous chemotherapy.</p> <p>A cultural model of chemotherapy was noted which stressed the value of suffering and pain as means of monitoring treatment effectiveness and even the possibility of cure. This framework differs from biomedical understanding of treatment in various aspects, with implications on anxiety levels experienced by the patients and the risk of recurrence.</p>
<p>Regnier Denois, Poirson, Nourissat, Jacquin, Guastalla and Chauvin, 2011, France</p>	<p>To describe and understand existing practice for capecitabine and to evaluate the perceptions and descriptions of patients and oncologist about the prescription of capecitabine</p>	<p>2 oncology hospitals, n=45</p>	<p>Qualitative study</p>	<ul style="list-style-type: none"> • Semi-directive interview technique to patients and oncologists • observational phase with patients 	<p>Content analysis</p>	<p>Adherence, which in this study was defined as being against not taking their treatment, generally seemed satisfactory. Results showed a wide diversity in the prescribers' practices, who often made decisions based on their experience of practice guidelines for intravenous chemotherapies. Although the results for the patients do not suggest deliberate non-adherence, they show poor observance of the dose schedule. The</p>

85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126

				<ul style="list-style-type: none"> • focus group interviews with patients 		study identified the patient's inability to recognise and report important signs of harmful toxicity.
Gerber, Hamann, Rasco, Woodruff and Craddock Lee, 2012, United States	To gain insight into patient perceptions of maintenance chemotherapy for advanced non-small cell lung cancer	Hospital (inpatient), n=47	Qualitative study	Focus group	Thematic content analysis	Five themes were identified: 1. survival benefits, disease control, and "buying time", 2. the importance of "doing something", 3. quality of life concerns, 4. the role of provider opinion/preference, 5. the importance of logistics.
Timmers, Boons, Moes-ten Hove, Smit, van de Ven, Aerts, Swart, Boven and Hugtenburg, 2015, Netherlands	To assess adherence to erlotinib treatment and evaluate experiences of patients as well as the relationship between medicine adherence, erlotinib exposure and symptoms	12 hospitals, n=62	Prospective observational cohort study	<ul style="list-style-type: none"> • Patients reported questionnaires • patients' medical file • adherence measured with medication event monitoring system (MEMS) • blood samples 	Mann-Whitney test, Fisher exact test	According to the Belief about Medicines Questionnaire (BMQ), 40% (n=25) of patients were classified as "accepting" treatment with erlotinib. 55% (n=34) of patients who had started their treatment with erlotinib, considered their treatment to be of high necessity and high concern. MEMS data of 55 patients revealed a mean adherence of 96.8 ± 4.0 %. Over one-third of patients had an adherence rate <95 %. At 1 month, 21 % of patients did not always correctly take erlotinib without food. Associated risk factors were older age, suboptimal adherence, ocular symptoms and stomatitis (all p < 0.05). After 1 month of treatment, fatigue (91%) and rash (86%) were the most common symptoms reported. AUCs of erlotinib was higher in patients with rash and patients with moderate-severe anorexia (both p < 0.05).
Gassmann, Kolbe and Brenner, 2016, Switzerland	To explore the experiences of patients undergoing oral chemotherapy and investigate the impact of oral chemotherapy on their daily life	Outpatients clinic of an urban hospital, n=6	Grounded theory	Open interviews	Constant comparison coding and categorising in line with paradigm model	Participants reported physical and emotional reluctance towards oral chemotherapy as well as toxic side effects. Feeling responsible emerged as a core phenomenon with influences from context and intervening conditions. All participants intended to adhere to treatment despite being a challenging task due to complex treatment regimen. Belief in the effectiveness of the therapy was a strengthening factor. Participants struggled between the necessity of adhering to oral chemotherapy and the practicality as well as emotional difficulties of daily life. Hence, patients developed coping strategies during the

127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168

						treatment journey. In consequence, oral chemotherapy was found to be omnipresent by determining the participants' thoughts and daily life.
Komatsu, Yagasaki, Yamauchi and Yamauchi, 2016, Japan	To explore the experiences of patients with breast cancer who had received chemotherapy to understand how they perceived the impact of the treatment on their daily lives	Outpatients of breast or oncology centre clinic in a hospital, n=17	Grounded theory	Semi-structured interviews	Analysis of transcripts by first coding and then labelling the meanings. Subcategories were identified to lead categories. Core categories emerged by connecting categories and subcategories.	Patients created personal safety nets for physical, emotional and social contexts during chemotherapy, even though they found everyday life to be more challenging because of the disease and side effects. Through their safety nets, the participants felt more confident and in control of their lives and were willing to take a positive approach towards making their lives meaningful. In anticipation of side effects of chemotherapy, participants "hibernated" and consumed minimal amount of energy. They also created a protective inner space in which they were able to tolerate fear and anxiety and exert self-control. In maintaining their daily routines, patients felt more confident to balance their lives and illness and helped them to tolerate uncertainty.
Timmers, Boons, Mangnus, van de Ven, Van den Berg, Aart B, Swart, Honeywell, Peters, Boven, Hugtenburg, 2016, Netherlands	To get insight into patients' experiences with the use of capecitabine in daily practice and the various aspects that govern adherence	10 hospitals, n=92	Prospective observational cohort study	<ul style="list-style-type: none"> Adherence assessed using a pill count, pharmacy data and dosing information obtained from the patients' medical file (PPP method) self-reported adherence measured using the Medication Adherence Report Scale. patients reported questionnaires blood samples 	X ² -test, Fisher's exact test, Logistic regression	Most patients (91%) had an adherence rate of ≥ 95 and $\leq 105\%$. Symptoms were frequently reported and the dosing regimen was adjusted by the physician at least once in 62% of patients (n=57). According to BMQ, 50% (n=46) of patients were classified as "accepting" capecitabine. These patients were associating their medicine with a high necessity and low concern prior to initiation of treatment. 44% (n=40) patients who had started their treatment with capecitabine considered their treatment to be of high necessity and high concern. According to the Brief Illness Perception Questionnaire (IPQ), patients were found to believe that treatment with capecitabine will help their illness and achieve treatment control. This is evidenced by the mean value which improved from baseline (7.8 \pm 1.8) to cycle 5 (8.0 \pm 1.6).

169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224


Appraisal item	Paper author		
		Timmers et al., 2016	Timmers et al., 2015
	Quality indicators		
	1. Did the study have a definition of lived experience?	N	N
Aim	2. Did the study have a clear statement of the aims and/or objectives of the research?	Y	Y
Ethics	3. Was ethics committee approval sought?	Y	Y
Study design	4. Was study design or method used justified and appropriate for the research question(s)?	Y	Y
Sample/ Participants	5. Were limitations of study design or method considered?	Y	P
	6. Was the sampling population and strategy clear and justified?	P	P
	7. Was the sample size justified?	N	N
	8. Were participant characteristics sufficiently described?	Y	P
	9. Was informed consent obtained from participants of the study?	Y	Y
	10. Were withdrawals and drop-outs reported in terms of numbers and/or reasons per group?	N	P
Data collection	11. Were the data collection tools described, piloted and validated?	Y	Y
Data analysis	12. Were analysis strategies clear and justified?	Y	P
Results/ Findings	13. Were the key findings of the study stated?	Y	Y
	14. Were the results of the study clearly explained and did the results address the original research question?	Y	P
	15. Were limitations (bias, confounders, generalisability) of findings considered?	Y	P
	16. Were all important outcomes considered so the results can be applied?	Y	P
	17. Were the conclusions supported by the findings?	Y	P
	18. Was conflict of interest reported?	Y	Y

Appendix 1: Methodological strengths and weakness of quantitative studies


Appraisal item	Quality indicators	Paper author								
		Bergkvist and Wengstrom, 2006	Regnier Denois et al., 2011	Gassmann et al., 2016	Gerber et al., 2012	Komatsu et al., 2016	Browall et al., 2006	Yokoyama dos Anjos and Zago, 2005	Bell, 2009	
Aim	1. Did the study state a clear statement of the aims of the research and relevant question(s) (aims, objectives)?	Y	P	Y	Y	Y	Y	Y	P	
	2. Did the study have a definition of lived experience?	N	N	N	N	N	N	N	N	
Ethics	3. Was ethics committee approval sought?	Y	Y	Y	Y	U	Y	Y	Y	
Study design	4. Was study design or method used justified and appropriate to address the aims of the research?	Y	Y	Y	Y	P	Y	Y	Y	
	5. Did the research seek to interpret or illuminate the actions and/or subjective experiences of research participants?	Y	Y	Y	Y	Y	Y	Y	Y	
	6. Were limitations of study design or method considered?	Y	Y	Y	Y	P	N	N	Y	
	7. Was the description provided detailed enough to allow the researcher or reader to interpret the meaning and context of what is being researched?	Y	Y	Y	Y	Y	P	P	Y	
	8. Was saturation of data discussed by the researcher?	N	N	Y	Y	Y	Y	N	N	
Sample/ Participants	9. Were the individuals selected to participate in the study likely to be representative of the target population?	P	Y	Y	Y	Y	Y	N	N	

	10. Was the sampling population and strategy clearly explained and justified?	P	Y	Y	Y	Y	Y	P	N
	11. Were participant recruitment strategy clearly described?	P	Y	N	P	Y	Y	P	N
	12. Was informed consent obtained from participants of the study?	N/A	Y	Y	Y	Y	Y	Y	Y
	13. Were participant characteristics sufficiently described?	Y	Y	Y	Y	Y	Y	Y	N
	14. Were the reasons for persons refusing to participate in the study provided?	N	Y	N	Y	N	N	N	P
Data analysis	15. Did the researcher explain the potential bias and influence on the research method and data collected?	Y	Y	N	Y	Y	N	N	P
	16. Was data analysis strategy clearly explained and justified?	Y	Y	Y	Y	Y	Y	P	Y
Results/ Findings	17. Were the results of the study clearly explained and did the results address the original research question?	Y	Y	Y	Y	Y	Y	P	Y
	18. Were limitations of findings (triangulation, respondent validation etc) considered	P	N	N	N	N	N	N	Y
	19. Was conflict of interest reported?	P	N	Y	N	N	N	N	N

Appendix 2: Methodological strengths and weakness of qualitative studies



Appendix 3: Stacked bar chart representing quality of quantitative studies



Appendix 4: Stacked bar chart representing quality of qualitative studies